In April 2022, Dr. Robert R. Ruffolo joined Cure Genetics's Scientific Advisory Board (SAB), where he will provide scientific guidance on our technology platform and R&D pipeline, collaborating to drive the internationalization of innovative products.
Dr. Ruffolo was formerly president and senior vice president (SVP) of R&D at Wyeth (now Pfizer), where he managed R&D team of over 9,000 scientists with an annual budget of $3 billion. Prior to Wyeth, he was SVP of R&D at SmithKline Beecham Pharmaceuticals (now GSK),. Dr. Ruffolo was instrumental in the discovery and development of many successful products, including Carvedilol, Ropinirole, Dobutamine and Eprosartan, which also earned him several prestigious awards, including the 2008 PhRMA Award for Discovery.